Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-TECHNE Corp Director's Dealing 2022

Aug 9, 2022

30718_dirs_2022-08-09_e4bff110-f2b3-4150-b018-52afeed3a42a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2022-08-07

Reporting Person: Hippel James (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-08-07 Common Stock M 3938 Acquired 14693 Direct
2022-08-07 Common Stock F 1938 $382.97 Disposed 12755 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-08-07 Restricted Stock Units $ M 3938 Disposed Common Stock (3938) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Options (Right to Buy) $125.0500 2024-08-09 Common Stock (47389) 47389 Direct
Stock Options (Right to Buy) $177.3200 2025-08-08 Common Stock (18066) 18066 Direct
Stock Options (Right to Buy) $177.3200 2025-08-08 Common Stock (24089) 24089 Direct
Stock Options (Right to Buy) $190.4100 2025-08-08 Common Stock (24089) 24089 Direct
Stock Options (Right to Buy) $190.4100 2026-08-07 Common Stock (26581) 26581 Direct
Restricted Stock Units $ Common Stock (3219) 3219 Direct
Stock Options (Right to Buy) $267.8700 2027-08-05 Common Stock (14360) 14360 Direct
Stock Options (Right to Buy) $267.8700 2027-08-05 Common Stock (19147) 19147 Direct
Stock Options (Right to Buy) $267.8700 2027-08-05 Common Stock (8325) 8325 Direct
Stock Options (Right to Buy) $267.8700 2027-08-05 Common Stock (8325) 8325 Direct
Restricted Stock Units $ Common Stock (1945) 1945 Direct
Stock Options (Right to Buy) $481.8200 2028-08-06 Common Stock (7600) 7600 Direct
Stock Options (Right to Buy) $481.8200 2028-08-06 Common Stock (10134) 10134 Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

F2: Fully exercisable.

F3: On 8/7/22, the Board of Directors certified vesting of 3,938 performance RSUs.

F4: Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.

F5: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F6: Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024.

F7: Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.

F8: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

F9: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F10: Options to purchase 2,534 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 2,533 shares vest on each of 8/6/2024 and 8/6/2025.